Evidence map›Paper›PMID 25203597›Full record

ArticleActa oncologica (Stockholm, Sweden)2015

Hodgkin lymphoma--a survey of children and adolescents treated in Sweden 1985-2009.

Annika Englund, Charlotte Hopstadius, Gunilla Enblad, Göran Gustafsson, Gustaf Ljungman

Abstract read
In one paragraph

Article in Acta oncologica (Stockholm, Sweden), 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Risk of Second Cancer in Hodgkin Lymphoma Survivors and Influence of Family History.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2017
    Article
  5. Residential Radon Exposure and Incidence of Childhood Lymphoma in Texas, 1995-2011.International journal of environmental research and public health · 2015
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Annika EnglundDepartment of Women's and Children's Health, Uppsala University , Uppsala , Sweden.
Charlotte Hopstadius
Gunilla Enblad
Göran Gustafsson
Gustaf Ljungman

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHodgkin lymphoma (HL) in children constitutes approximately 30% of all pediatric lymphomas in Sweden. The chance of cure is high, but the frequency of late effects has been considerable. Over recent years, efforts have been made to reduce treatment with maintained survival. MATERIAL AND

methodsAll patients 0-17 years, identified in the Swedish Childhood Cancer Register as diagnosed between 1985 and 2009, were included. The material was analyzed using descriptive statistics and for survival estimates the Kaplan-Meier method was used.

resultsThree hundred and thirty-four patients were identified during this time period. The median age was 14 years. Male sex was over-represented, especially in lower age groups and in nodular lymphocyte predominant Hodgkin lymphoma (NLPHL). In nodular sclerosis and in age group 15-17 years, female sex dominated. Most of the cases presented in stages I or II. B-symptoms were present in 38% of cHL, but only in 7% of NLPHL. The number of patients receiving radiotherapy has been significantly reduced during the period studied. The relapse rate in cHL was 10 ± 2% and in NLPHL 16 ± 7%. The relapse rate was significantly higher in cHL stage IIB compared to other stages in the same therapy group. In cHL 6% died, and in NLPHL 0%. The 5-, 10- and 20-year overall survival estimates in cHL were 96 ± 1%, 95 ± 1% and 90 ± 3%, respectively, with no significant difference when comparing different treatment regimens and time periods. The 5- and 10-year overall survival after relapse in cHL was 81 ± 8% and 75 ± 10%, respectively.

conclusionDuring the period studied there is no indication of a decline in survival despite changes in treatment. Survival rates in Sweden are high, and even after relapse chances of cure are high. We were not able to identify any characteristics specific for the group of patients that did not survive.

Indexed as

AdolescentAntineoplastic Combined Chemotherapy ProtocolsBleomycinChildChild, PreschoolDacarbazineDoxorubicinFemaleHodgkin DiseaseHumansIncidenceInfantInfant, NewbornMaleMechlorethaminePrednisoneBleomycinDacarbazineDoxorubicinMechlorethaminePrednisoneProcarbazineVinblastineVincristine

Identifiers

PMID25203597
PMCPMC4364274

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.